Icon initiated with bullish view at Truist, here’s why

Truist initiated coverage of Icon with a Buy rating and $357 price target. The analyst says the company is well positioned to benefit from the favorable long-term industry tailwinds of pharma vendor consolidation, continued trial outsourcing, growth in pharma spending budgets, and shift towards complex therapeutics. Icon is poised to deliver effective delivery models with its partners to reduce sponsor development time and resources, As previously reported,